LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis
of the eyelashes by increasing their growth, including length, thickness, and darkness.
Important Safety Information
Warnings and Precautions:
In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin
analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE®
may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN®
for IOP reduction should only use LATISSE® after consulting with their physician
and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when bimatoprost solution was administered.
Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes.
There is the potential for hair growth to occur in areas where LATISSE®
solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the
skin of the upper eyelid margin at the base of the eyelashes.
LATISSE® solution should be used with caution in patients with active intraocular
inflammation (eg, uveitis) because the inflammation may be exacerbated.
LATISSE® contains benzalkonium chloride,
which may be absorbed by soft contact lenses. Contact lenses should be removed prior to
application of solution and may be reinserted 15 minutes following its administration.
The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation,
ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.
Postmarketing Experience: The following reactions have been identified during postmarketing use of
LATISSE® in clinical practice: burning sensation (eyelid),
erythema periorbital, eye swelling, eyelid irritation, eyelid edema, eyelid pruritus, iris hyperpigmentation,
lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections
of eyelashes, and temporary eyelash breakage, respectively), rash (including macular, erythematous, and pruritic
limited to the eyelids and periorbital region), skin discoloration (periorbital), and vision blurred.
Use in Specific Populations: Use in pediatric patients below the age of 16 years is not recommended
because of potential safety concerns related to increased pigmentation following long-term chronic use.
Click here for full Prescribing Information.
All women featured in this module are paid LATISSE® patients. Their lashes have not
been retouched. Individual results may vary.
©2012 Allergan, Inc., Irvine, CA 92612 ®
and ™ marks owned by Allergan, Inc.